drugset / Trial / NCT06907173
Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)
Phase 3
Recruiting
770 enrolled
University of Virginia
Children's National Research Institute · collabMassachusetts General Hospital · collabMedical University of South Carolina · collabUniversity of Michigan · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The goal of this clinical trial is to determine if treatment of patients with two doses of ketamine plus levetiracetam versus levetiracetam alone leads to more effective control of status epilepticus.
Timeline
- Start
- 2026-03-06
- Primary completion
- 2029-06
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ketamine | Small molecule | 1 mg/kg | — |
| Subject | Ketamine | Small molecule | 3 mg/kg | — |
| Background | Levetiracetam | Other / unclassified | 60 mg/kg | — |
Indications
No indication recorded.